BRKR Stock Recent News

Bruker Corporation 6.375 PREF SER A is a new 6.375% mandatory convertible preferred stock from Bruker, offering fixed income but closely tied to BRKR's common stock performance. Bruker's fundamentals have weakened, with declining performance and a dividend cushion that's thinner than ideal for preferred holders. Option-adjusted yield to maturity is unappealing versus peer term preferreds of comparable maturity, especially given the lack of 1940 Act protections.

Medical device and diagnostics company Bruker (BRKR -11.68%) wasn't looking like the cure for any investor's ailments on Wednesday. The stock was hit with an assertive sell-off from the market, leaving it with a nearly 12% price decline on the session.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced the pricing of its previously announced public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker has granted the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock. The offering is expected to close on or about September 8.

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker expects to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock, solely to cover over-allotments, if any.

Michael Burry, the legendary “Big Short” investor and founder of Scion Asset Management has revealed a substantial reshuffle in his Q2 2025 holdings, adding heavyweight names across healthcare, retail, biotech, and e-commerce while trimming his largest position.

Bruker faces significant headwinds due to NIH funding cuts, heavy reliance on academia, and declining financial performance versus peers. Despite operational challenges and a sharp drop in valuation, Bruker's NMR technology moat and long-term potential remain intact. I'm accumulating shares gradually at these low valuations, confident in mean reversion and management's ability to consolidate acquisitions.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop.

BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.

Explore Bruker's (BRKR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.